nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—HTR2B—Sorafenib—kidney cancer	0.0943	0.413	CbGbCtD
Pramipexole—SLC22A2—Vinblastine—kidney cancer	0.0725	0.318	CbGbCtD
Pramipexole—HTR2C—Sorafenib—kidney cancer	0.0614	0.269	CbGbCtD
Pramipexole—SLC22A2—nephron—kidney cancer	0.00962	0.277	CbGeAlD
Pramipexole—HTR2A—urine—kidney cancer	0.00268	0.0772	CbGeAlD
Pramipexole—SLC22A2—nephron tubule—kidney cancer	0.00208	0.0597	CbGeAlD
Pramipexole—SLC22A2—renal system—kidney cancer	0.00189	0.0543	CbGeAlD
Pramipexole—SLC22A2—kidney—kidney cancer	0.00182	0.0525	CbGeAlD
Pramipexole—SLC22A2—cortex of kidney—kidney cancer	0.00178	0.0511	CbGeAlD
Pramipexole—SLC22A1—renal system—kidney cancer	0.00133	0.0384	CbGeAlD
Pramipexole—SLC22A1—kidney—kidney cancer	0.00129	0.0371	CbGeAlD
Pramipexole—HTR1D—kidney—kidney cancer	0.00128	0.0368	CbGeAlD
Pramipexole—HTR2B—cortex of kidney—kidney cancer	0.00116	0.0333	CbGeAlD
Pramipexole—HTR1A—renal system—kidney cancer	0.0011	0.0317	CbGeAlD
Pramipexole—ADRA2C—nephron tubule—kidney cancer	0.00106	0.0306	CbGeAlD
Pramipexole—ADRA2C—renal system—kidney cancer	0.000967	0.0278	CbGeAlD
Pramipexole—ADRA2C—kidney—kidney cancer	0.000935	0.0269	CbGeAlD
Pramipexole—ADRA2C—cortex of kidney—kidney cancer	0.000911	0.0262	CbGeAlD
Pramipexole—ADRA2C—cardiac atrium—kidney cancer	0.000866	0.0249	CbGeAlD
Pramipexole—ADRA2A—cortex of kidney—kidney cancer	0.000727	0.0209	CbGeAlD
Pramipexole—ADRA2A—gonad—kidney cancer	0.000692	0.0199	CbGeAlD
Pramipexole—ADRA2A—cardiac atrium—kidney cancer	0.000691	0.0199	CbGeAlD
Pramipexole—HTR2A—renal system—kidney cancer	0.000656	0.0189	CbGeAlD
Pramipexole—HTR2A—kidney—kidney cancer	0.000634	0.0183	CbGeAlD
Pramipexole—HTR2A—gonad—kidney cancer	0.000588	0.0169	CbGeAlD
Pramipexole—Oedema—Paclitaxel—kidney cancer	0.000109	0.000159	CcSEcCtD
Pramipexole—Abdominal pain—Vincristine—kidney cancer	0.000108	0.000158	CcSEcCtD
Pramipexole—Body temperature increased—Vincristine—kidney cancer	0.000108	0.000158	CcSEcCtD
Pramipexole—Infection—Paclitaxel—kidney cancer	0.000108	0.000158	CcSEcCtD
Pramipexole—Flatulence—Capecitabine—kidney cancer	0.000108	0.000157	CcSEcCtD
Pramipexole—Dry skin—Doxorubicin—kidney cancer	0.000107	0.000157	CcSEcCtD
Pramipexole—Dysgeusia—Capecitabine—kidney cancer	0.000107	0.000156	CcSEcCtD
Pramipexole—Dizziness—Sunitinib—kidney cancer	0.000107	0.000156	CcSEcCtD
Pramipexole—Feeling abnormal—Gemcitabine—kidney cancer	0.000107	0.000156	CcSEcCtD
Pramipexole—Shock—Paclitaxel—kidney cancer	0.000107	0.000156	CcSEcCtD
Pramipexole—Vomiting—Sorafenib—kidney cancer	0.000107	0.000156	CcSEcCtD
Pramipexole—Abdominal pain upper—Doxorubicin—kidney cancer	0.000107	0.000156	CcSEcCtD
Pramipexole—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000107	0.000156	CcSEcCtD
Pramipexole—Nervous system disorder—Paclitaxel—kidney cancer	0.000106	0.000156	CcSEcCtD
Pramipexole—Hypokalaemia—Doxorubicin—kidney cancer	0.000106	0.000156	CcSEcCtD
Pramipexole—Thrombocytopenia—Paclitaxel—kidney cancer	0.000106	0.000156	CcSEcCtD
Pramipexole—Tachycardia—Paclitaxel—kidney cancer	0.000106	0.000155	CcSEcCtD
Pramipexole—Rash—Sorafenib—kidney cancer	0.000106	0.000155	CcSEcCtD
Pramipexole—Dermatitis—Sorafenib—kidney cancer	0.000106	0.000155	CcSEcCtD
Pramipexole—Back pain—Capecitabine—kidney cancer	0.000106	0.000154	CcSEcCtD
Pramipexole—Breast disorder—Doxorubicin—kidney cancer	0.000106	0.000154	CcSEcCtD
Pramipexole—Skin disorder—Paclitaxel—kidney cancer	0.000105	0.000154	CcSEcCtD
Pramipexole—Headache—Sorafenib—kidney cancer	0.000105	0.000154	CcSEcCtD
Pramipexole—Muscle spasms—Capecitabine—kidney cancer	0.000105	0.000154	CcSEcCtD
Pramipexole—Hyperhidrosis—Paclitaxel—kidney cancer	0.000105	0.000154	CcSEcCtD
Pramipexole—Diarrhoea—Dactinomycin—kidney cancer	0.000105	0.000153	CcSEcCtD
Pramipexole—Nasopharyngitis—Doxorubicin—kidney cancer	0.000104	0.000153	CcSEcCtD
Pramipexole—Anorexia—Paclitaxel—kidney cancer	0.000103	0.000151	CcSEcCtD
Pramipexole—Gastritis—Doxorubicin—kidney cancer	0.000103	0.000151	CcSEcCtD
Pramipexole—Muscular weakness—Doxorubicin—kidney cancer	0.000103	0.000151	CcSEcCtD
Pramipexole—Vision blurred—Capecitabine—kidney cancer	0.000103	0.000151	CcSEcCtD
Pramipexole—Vomiting—Sunitinib—kidney cancer	0.000103	0.00015	CcSEcCtD
Pramipexole—Body temperature increased—Gemcitabine—kidney cancer	0.000103	0.00015	CcSEcCtD
Pramipexole—Tremor—Capecitabine—kidney cancer	0.000102	0.00015	CcSEcCtD
Pramipexole—Rash—Sunitinib—kidney cancer	0.000102	0.000149	CcSEcCtD
Pramipexole—Dermatitis—Sunitinib—kidney cancer	0.000102	0.000149	CcSEcCtD
Pramipexole—Abdominal distension—Doxorubicin—kidney cancer	0.000102	0.000149	CcSEcCtD
Pramipexole—Hypotension—Paclitaxel—kidney cancer	0.000101	0.000148	CcSEcCtD
Pramipexole—Ill-defined disorder—Capecitabine—kidney cancer	0.000101	0.000148	CcSEcCtD
Pramipexole—Headache—Sunitinib—kidney cancer	0.000101	0.000148	CcSEcCtD
Pramipexole—Asthma—Doxorubicin—kidney cancer	0.000101	0.000148	CcSEcCtD
Pramipexole—Dysphagia—Doxorubicin—kidney cancer	0.000101	0.000148	CcSEcCtD
Pramipexole—Influenza—Doxorubicin—kidney cancer	0.000101	0.000148	CcSEcCtD
Pramipexole—Anaemia—Capecitabine—kidney cancer	0.000101	0.000148	CcSEcCtD
Pramipexole—Hypersensitivity—Vincristine—kidney cancer	0.000101	0.000147	CcSEcCtD
Pramipexole—Nausea—Sorafenib—kidney cancer	9.98e-05	0.000146	CcSEcCtD
Pramipexole—Pancreatitis—Doxorubicin—kidney cancer	9.9e-05	0.000145	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Paclitaxel—kidney cancer	9.89e-05	0.000145	CcSEcCtD
Pramipexole—Malaise—Capecitabine—kidney cancer	9.85e-05	0.000144	CcSEcCtD
Pramipexole—Angina pectoris—Doxorubicin—kidney cancer	9.84e-05	0.000144	CcSEcCtD
Pramipexole—Insomnia—Paclitaxel—kidney cancer	9.82e-05	0.000144	CcSEcCtD
Pramipexole—Vertigo—Capecitabine—kidney cancer	9.81e-05	0.000143	CcSEcCtD
Pramipexole—Asthenia—Vincristine—kidney cancer	9.81e-05	0.000143	CcSEcCtD
Pramipexole—Syncope—Capecitabine—kidney cancer	9.79e-05	0.000143	CcSEcCtD
Pramipexole—Leukopenia—Capecitabine—kidney cancer	9.77e-05	0.000143	CcSEcCtD
Pramipexole—Paraesthesia—Paclitaxel—kidney cancer	9.75e-05	0.000143	CcSEcCtD
Pramipexole—Vomiting—Dactinomycin—kidney cancer	9.73e-05	0.000142	CcSEcCtD
Pramipexole—Bronchitis—Doxorubicin—kidney cancer	9.71e-05	0.000142	CcSEcCtD
Pramipexole—Dyspnoea—Paclitaxel—kidney cancer	9.68e-05	0.000142	CcSEcCtD
Pramipexole—Somnolence—Paclitaxel—kidney cancer	9.65e-05	0.000141	CcSEcCtD
Pramipexole—Palpitations—Capecitabine—kidney cancer	9.65e-05	0.000141	CcSEcCtD
Pramipexole—Rash—Dactinomycin—kidney cancer	9.65e-05	0.000141	CcSEcCtD
Pramipexole—Nausea—Sunitinib—kidney cancer	9.6e-05	0.00014	CcSEcCtD
Pramipexole—Loss of consciousness—Capecitabine—kidney cancer	9.6e-05	0.00014	CcSEcCtD
Pramipexole—Dyspepsia—Paclitaxel—kidney cancer	9.56e-05	0.00014	CcSEcCtD
Pramipexole—Cough—Capecitabine—kidney cancer	9.53e-05	0.000139	CcSEcCtD
Pramipexole—Dysuria—Doxorubicin—kidney cancer	9.44e-05	0.000138	CcSEcCtD
Pramipexole—Decreased appetite—Paclitaxel—kidney cancer	9.44e-05	0.000138	CcSEcCtD
Pramipexole—Hypertension—Capecitabine—kidney cancer	9.43e-05	0.000138	CcSEcCtD
Pramipexole—Upper respiratory tract infection—Doxorubicin—kidney cancer	9.39e-05	0.000137	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Paclitaxel—kidney cancer	9.37e-05	0.000137	CcSEcCtD
Pramipexole—Fatigue—Paclitaxel—kidney cancer	9.36e-05	0.000137	CcSEcCtD
Pramipexole—Diarrhoea—Vincristine—kidney cancer	9.35e-05	0.000137	CcSEcCtD
Pramipexole—Pollakiuria—Doxorubicin—kidney cancer	9.33e-05	0.000136	CcSEcCtD
Pramipexole—Asthenia—Gemcitabine—kidney cancer	9.3e-05	0.000136	CcSEcCtD
Pramipexole—Myalgia—Capecitabine—kidney cancer	9.29e-05	0.000136	CcSEcCtD
Pramipexole—Chest pain—Capecitabine—kidney cancer	9.29e-05	0.000136	CcSEcCtD
Pramipexole—Arthralgia—Capecitabine—kidney cancer	9.29e-05	0.000136	CcSEcCtD
Pramipexole—Pain—Paclitaxel—kidney cancer	9.28e-05	0.000136	CcSEcCtD
Pramipexole—Constipation—Paclitaxel—kidney cancer	9.28e-05	0.000136	CcSEcCtD
Pramipexole—Anxiety—Capecitabine—kidney cancer	9.26e-05	0.000136	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	9.23e-05	0.000135	CcSEcCtD
Pramipexole—Photosensitivity reaction—Doxorubicin—kidney cancer	9.22e-05	0.000135	CcSEcCtD
Pramipexole—Weight increased—Doxorubicin—kidney cancer	9.19e-05	0.000134	CcSEcCtD
Pramipexole—Discomfort—Capecitabine—kidney cancer	9.18e-05	0.000134	CcSEcCtD
Pramipexole—Pruritus—Gemcitabine—kidney cancer	9.18e-05	0.000134	CcSEcCtD
Pramipexole—Weight decreased—Doxorubicin—kidney cancer	9.14e-05	0.000134	CcSEcCtD
Pramipexole—Hyperglycaemia—Doxorubicin—kidney cancer	9.11e-05	0.000133	CcSEcCtD
Pramipexole—Dry mouth—Capecitabine—kidney cancer	9.09e-05	0.000133	CcSEcCtD
Pramipexole—Nausea—Dactinomycin—kidney cancer	9.09e-05	0.000133	CcSEcCtD
Pramipexole—Pneumonia—Doxorubicin—kidney cancer	9.06e-05	0.000133	CcSEcCtD
Pramipexole—Dizziness—Vincristine—kidney cancer	9.04e-05	0.000132	CcSEcCtD
Pramipexole—Infestation NOS—Doxorubicin—kidney cancer	9.01e-05	0.000132	CcSEcCtD
Pramipexole—Infestation—Doxorubicin—kidney cancer	9.01e-05	0.000132	CcSEcCtD
Pramipexole—Drowsiness—Doxorubicin—kidney cancer	9.01e-05	0.000132	CcSEcCtD
Pramipexole—Confusional state—Capecitabine—kidney cancer	8.98e-05	0.000131	CcSEcCtD
Pramipexole—Feeling abnormal—Paclitaxel—kidney cancer	8.95e-05	0.000131	CcSEcCtD
Pramipexole—Oedema—Capecitabine—kidney cancer	8.91e-05	0.00013	CcSEcCtD
Pramipexole—Gastrointestinal pain—Paclitaxel—kidney cancer	8.88e-05	0.00013	CcSEcCtD
Pramipexole—Diarrhoea—Gemcitabine—kidney cancer	8.87e-05	0.00013	CcSEcCtD
Pramipexole—Renal failure—Doxorubicin—kidney cancer	8.85e-05	0.00013	CcSEcCtD
Pramipexole—Infection—Capecitabine—kidney cancer	8.85e-05	0.000129	CcSEcCtD
Pramipexole—Neuropathy peripheral—Doxorubicin—kidney cancer	8.83e-05	0.000129	CcSEcCtD
Pramipexole—Shock—Capecitabine—kidney cancer	8.77e-05	0.000128	CcSEcCtD
Pramipexole—Conjunctivitis—Doxorubicin—kidney cancer	8.75e-05	0.000128	CcSEcCtD
Pramipexole—Urinary tract infection—Doxorubicin—kidney cancer	8.75e-05	0.000128	CcSEcCtD
Pramipexole—Nervous system disorder—Capecitabine—kidney cancer	8.74e-05	0.000128	CcSEcCtD
Pramipexole—Thrombocytopenia—Capecitabine—kidney cancer	8.72e-05	0.000128	CcSEcCtD
Pramipexole—Tachycardia—Capecitabine—kidney cancer	8.7e-05	0.000127	CcSEcCtD
Pramipexole—Vomiting—Vincristine—kidney cancer	8.69e-05	0.000127	CcSEcCtD
Pramipexole—Skin disorder—Capecitabine—kidney cancer	8.65e-05	0.000127	CcSEcCtD
Pramipexole—Sweating—Doxorubicin—kidney cancer	8.63e-05	0.000126	CcSEcCtD
Pramipexole—Urticaria—Paclitaxel—kidney cancer	8.63e-05	0.000126	CcSEcCtD
Pramipexole—Rash—Vincristine—kidney cancer	8.62e-05	0.000126	CcSEcCtD
Pramipexole—Hyperhidrosis—Capecitabine—kidney cancer	8.61e-05	0.000126	CcSEcCtD
Pramipexole—Dermatitis—Vincristine—kidney cancer	8.61e-05	0.000126	CcSEcCtD
Pramipexole—Haematuria—Doxorubicin—kidney cancer	8.59e-05	0.000126	CcSEcCtD
Pramipexole—Body temperature increased—Paclitaxel—kidney cancer	8.58e-05	0.000126	CcSEcCtD
Pramipexole—Abdominal pain—Paclitaxel—kidney cancer	8.58e-05	0.000126	CcSEcCtD
Pramipexole—Headache—Vincristine—kidney cancer	8.56e-05	0.000125	CcSEcCtD
Pramipexole—Hepatobiliary disease—Doxorubicin—kidney cancer	8.52e-05	0.000125	CcSEcCtD
Pramipexole—Epistaxis—Doxorubicin—kidney cancer	8.49e-05	0.000124	CcSEcCtD
Pramipexole—Anorexia—Capecitabine—kidney cancer	8.49e-05	0.000124	CcSEcCtD
Pramipexole—Sinusitis—Doxorubicin—kidney cancer	8.45e-05	0.000124	CcSEcCtD
Pramipexole—Hypotension—Capecitabine—kidney cancer	8.33e-05	0.000122	CcSEcCtD
Pramipexole—Vomiting—Gemcitabine—kidney cancer	8.25e-05	0.000121	CcSEcCtD
Pramipexole—Bradycardia—Doxorubicin—kidney cancer	8.23e-05	0.00012	CcSEcCtD
Pramipexole—Rash—Gemcitabine—kidney cancer	8.18e-05	0.00012	CcSEcCtD
Pramipexole—Dermatitis—Gemcitabine—kidney cancer	8.17e-05	0.00012	CcSEcCtD
Pramipexole—Headache—Gemcitabine—kidney cancer	8.12e-05	0.000119	CcSEcCtD
Pramipexole—Nausea—Vincristine—kidney cancer	8.12e-05	0.000119	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Capecitabine—kidney cancer	8.12e-05	0.000119	CcSEcCtD
Pramipexole—Rhinitis—Doxorubicin—kidney cancer	8.1e-05	0.000119	CcSEcCtD
Pramipexole—Insomnia—Capecitabine—kidney cancer	8.06e-05	0.000118	CcSEcCtD
Pramipexole—Hypoaesthesia—Doxorubicin—kidney cancer	8.04e-05	0.000118	CcSEcCtD
Pramipexole—Pharyngitis—Doxorubicin—kidney cancer	8.02e-05	0.000117	CcSEcCtD
Pramipexole—Paraesthesia—Capecitabine—kidney cancer	8e-05	0.000117	CcSEcCtD
Pramipexole—Hypersensitivity—Paclitaxel—kidney cancer	8e-05	0.000117	CcSEcCtD
Pramipexole—Urinary tract disorder—Doxorubicin—kidney cancer	7.98e-05	0.000117	CcSEcCtD
Pramipexole—Oedema peripheral—Doxorubicin—kidney cancer	7.96e-05	0.000117	CcSEcCtD
Pramipexole—Connective tissue disorder—Doxorubicin—kidney cancer	7.94e-05	0.000116	CcSEcCtD
Pramipexole—Dyspnoea—Capecitabine—kidney cancer	7.94e-05	0.000116	CcSEcCtD
Pramipexole—Urethral disorder—Doxorubicin—kidney cancer	7.92e-05	0.000116	CcSEcCtD
Pramipexole—Dyspepsia—Capecitabine—kidney cancer	7.84e-05	0.000115	CcSEcCtD
Pramipexole—Visual impairment—Doxorubicin—kidney cancer	7.79e-05	0.000114	CcSEcCtD
Pramipexole—Asthenia—Paclitaxel—kidney cancer	7.79e-05	0.000114	CcSEcCtD
Pramipexole—Decreased appetite—Capecitabine—kidney cancer	7.75e-05	0.000113	CcSEcCtD
Pramipexole—Nausea—Gemcitabine—kidney cancer	7.7e-05	0.000113	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Capecitabine—kidney cancer	7.69e-05	0.000113	CcSEcCtD
Pramipexole—Fatigue—Capecitabine—kidney cancer	7.68e-05	0.000112	CcSEcCtD
Pramipexole—Pruritus—Paclitaxel—kidney cancer	7.68e-05	0.000112	CcSEcCtD
Pramipexole—Constipation—Capecitabine—kidney cancer	7.62e-05	0.000111	CcSEcCtD
Pramipexole—Pain—Capecitabine—kidney cancer	7.62e-05	0.000111	CcSEcCtD
Pramipexole—Eye disorder—Doxorubicin—kidney cancer	7.56e-05	0.000111	CcSEcCtD
Pramipexole—Tinnitus—Doxorubicin—kidney cancer	7.54e-05	0.00011	CcSEcCtD
Pramipexole—Flushing—Doxorubicin—kidney cancer	7.5e-05	0.00011	CcSEcCtD
Pramipexole—Cardiac disorder—Doxorubicin—kidney cancer	7.5e-05	0.00011	CcSEcCtD
Pramipexole—Diarrhoea—Paclitaxel—kidney cancer	7.43e-05	0.000109	CcSEcCtD
Pramipexole—Feeling abnormal—Capecitabine—kidney cancer	7.34e-05	0.000107	CcSEcCtD
Pramipexole—Angiopathy—Doxorubicin—kidney cancer	7.33e-05	0.000107	CcSEcCtD
Pramipexole—Immune system disorder—Doxorubicin—kidney cancer	7.3e-05	0.000107	CcSEcCtD
Pramipexole—Gastrointestinal pain—Capecitabine—kidney cancer	7.29e-05	0.000107	CcSEcCtD
Pramipexole—Mediastinal disorder—Doxorubicin—kidney cancer	7.29e-05	0.000107	CcSEcCtD
Pramipexole—Chills—Doxorubicin—kidney cancer	7.25e-05	0.000106	CcSEcCtD
Pramipexole—Dizziness—Paclitaxel—kidney cancer	7.18e-05	0.000105	CcSEcCtD
Pramipexole—Alopecia—Doxorubicin—kidney cancer	7.14e-05	0.000105	CcSEcCtD
Pramipexole—Mental disorder—Doxorubicin—kidney cancer	7.08e-05	0.000104	CcSEcCtD
Pramipexole—Urticaria—Capecitabine—kidney cancer	7.08e-05	0.000104	CcSEcCtD
Pramipexole—Abdominal pain—Capecitabine—kidney cancer	7.04e-05	0.000103	CcSEcCtD
Pramipexole—Body temperature increased—Capecitabine—kidney cancer	7.04e-05	0.000103	CcSEcCtD
Pramipexole—Erythema—Doxorubicin—kidney cancer	7.04e-05	0.000103	CcSEcCtD
Pramipexole—Malnutrition—Doxorubicin—kidney cancer	7.04e-05	0.000103	CcSEcCtD
Pramipexole—Flatulence—Doxorubicin—kidney cancer	6.93e-05	0.000101	CcSEcCtD
Pramipexole—Tension—Doxorubicin—kidney cancer	6.91e-05	0.000101	CcSEcCtD
Pramipexole—Vomiting—Paclitaxel—kidney cancer	6.9e-05	0.000101	CcSEcCtD
Pramipexole—Dysgeusia—Doxorubicin—kidney cancer	6.89e-05	0.000101	CcSEcCtD
Pramipexole—Rash—Paclitaxel—kidney cancer	6.85e-05	0.0001	CcSEcCtD
Pramipexole—Dermatitis—Paclitaxel—kidney cancer	6.84e-05	0.0001	CcSEcCtD
Pramipexole—Nervousness—Doxorubicin—kidney cancer	6.84e-05	0.0001	CcSEcCtD
Pramipexole—Back pain—Doxorubicin—kidney cancer	6.81e-05	9.96e-05	CcSEcCtD
Pramipexole—Headache—Paclitaxel—kidney cancer	6.8e-05	9.95e-05	CcSEcCtD
Pramipexole—Muscle spasms—Doxorubicin—kidney cancer	6.77e-05	9.9e-05	CcSEcCtD
Pramipexole—Vision blurred—Doxorubicin—kidney cancer	6.63e-05	9.7e-05	CcSEcCtD
Pramipexole—Hypersensitivity—Capecitabine—kidney cancer	6.56e-05	9.6e-05	CcSEcCtD
Pramipexole—Ill-defined disorder—Doxorubicin—kidney cancer	6.53e-05	9.55e-05	CcSEcCtD
Pramipexole—Anaemia—Doxorubicin—kidney cancer	6.5e-05	9.52e-05	CcSEcCtD
Pramipexole—Agitation—Doxorubicin—kidney cancer	6.47e-05	9.46e-05	CcSEcCtD
Pramipexole—Nausea—Paclitaxel—kidney cancer	6.45e-05	9.43e-05	CcSEcCtD
Pramipexole—Asthenia—Capecitabine—kidney cancer	6.39e-05	9.35e-05	CcSEcCtD
Pramipexole—Malaise—Doxorubicin—kidney cancer	6.35e-05	9.28e-05	CcSEcCtD
Pramipexole—Vertigo—Doxorubicin—kidney cancer	6.32e-05	9.25e-05	CcSEcCtD
Pramipexole—Syncope—Doxorubicin—kidney cancer	6.31e-05	9.23e-05	CcSEcCtD
Pramipexole—Pruritus—Capecitabine—kidney cancer	6.3e-05	9.22e-05	CcSEcCtD
Pramipexole—Leukopenia—Doxorubicin—kidney cancer	6.3e-05	9.22e-05	CcSEcCtD
Pramipexole—Palpitations—Doxorubicin—kidney cancer	6.22e-05	9.1e-05	CcSEcCtD
Pramipexole—Loss of consciousness—Doxorubicin—kidney cancer	6.19e-05	9.05e-05	CcSEcCtD
Pramipexole—Cough—Doxorubicin—kidney cancer	6.14e-05	8.98e-05	CcSEcCtD
Pramipexole—Convulsion—Doxorubicin—kidney cancer	6.1e-05	8.92e-05	CcSEcCtD
Pramipexole—Diarrhoea—Capecitabine—kidney cancer	6.1e-05	8.92e-05	CcSEcCtD
Pramipexole—Hypertension—Doxorubicin—kidney cancer	6.08e-05	8.89e-05	CcSEcCtD
Pramipexole—Myalgia—Doxorubicin—kidney cancer	5.99e-05	8.76e-05	CcSEcCtD
Pramipexole—Chest pain—Doxorubicin—kidney cancer	5.99e-05	8.76e-05	CcSEcCtD
Pramipexole—Arthralgia—Doxorubicin—kidney cancer	5.99e-05	8.76e-05	CcSEcCtD
Pramipexole—Anxiety—Doxorubicin—kidney cancer	5.97e-05	8.73e-05	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	5.95e-05	8.7e-05	CcSEcCtD
Pramipexole—Discomfort—Doxorubicin—kidney cancer	5.92e-05	8.66e-05	CcSEcCtD
Pramipexole—Dizziness—Capecitabine—kidney cancer	5.89e-05	8.62e-05	CcSEcCtD
Pramipexole—Dry mouth—Doxorubicin—kidney cancer	5.86e-05	8.57e-05	CcSEcCtD
Pramipexole—Confusional state—Doxorubicin—kidney cancer	5.79e-05	8.47e-05	CcSEcCtD
Pramipexole—Oedema—Doxorubicin—kidney cancer	5.74e-05	8.4e-05	CcSEcCtD
Pramipexole—Infection—Doxorubicin—kidney cancer	5.71e-05	8.35e-05	CcSEcCtD
Pramipexole—Vomiting—Capecitabine—kidney cancer	5.67e-05	8.29e-05	CcSEcCtD
Pramipexole—Shock—Doxorubicin—kidney cancer	5.65e-05	8.27e-05	CcSEcCtD
Pramipexole—Nervous system disorder—Doxorubicin—kidney cancer	5.63e-05	8.24e-05	CcSEcCtD
Pramipexole—Thrombocytopenia—Doxorubicin—kidney cancer	5.62e-05	8.23e-05	CcSEcCtD
Pramipexole—Rash—Capecitabine—kidney cancer	5.62e-05	8.22e-05	CcSEcCtD
Pramipexole—Dermatitis—Capecitabine—kidney cancer	5.61e-05	8.21e-05	CcSEcCtD
Pramipexole—Tachycardia—Doxorubicin—kidney cancer	5.61e-05	8.2e-05	CcSEcCtD
Pramipexole—Headache—Capecitabine—kidney cancer	5.58e-05	8.17e-05	CcSEcCtD
Pramipexole—Skin disorder—Doxorubicin—kidney cancer	5.58e-05	8.16e-05	CcSEcCtD
Pramipexole—Hyperhidrosis—Doxorubicin—kidney cancer	5.55e-05	8.12e-05	CcSEcCtD
Pramipexole—Anorexia—Doxorubicin—kidney cancer	5.47e-05	8.01e-05	CcSEcCtD
Pramipexole—Hypotension—Doxorubicin—kidney cancer	5.37e-05	7.85e-05	CcSEcCtD
Pramipexole—Nausea—Capecitabine—kidney cancer	5.29e-05	7.74e-05	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Doxorubicin—kidney cancer	5.23e-05	7.66e-05	CcSEcCtD
Pramipexole—Insomnia—Doxorubicin—kidney cancer	5.19e-05	7.6e-05	CcSEcCtD
Pramipexole—Paraesthesia—Doxorubicin—kidney cancer	5.16e-05	7.54e-05	CcSEcCtD
Pramipexole—Dyspnoea—Doxorubicin—kidney cancer	5.12e-05	7.49e-05	CcSEcCtD
Pramipexole—Somnolence—Doxorubicin—kidney cancer	5.11e-05	7.47e-05	CcSEcCtD
Pramipexole—Dyspepsia—Doxorubicin—kidney cancer	5.06e-05	7.4e-05	CcSEcCtD
Pramipexole—Decreased appetite—Doxorubicin—kidney cancer	4.99e-05	7.3e-05	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Doxorubicin—kidney cancer	4.96e-05	7.25e-05	CcSEcCtD
Pramipexole—Fatigue—Doxorubicin—kidney cancer	4.95e-05	7.24e-05	CcSEcCtD
Pramipexole—Constipation—Doxorubicin—kidney cancer	4.91e-05	7.19e-05	CcSEcCtD
Pramipexole—Pain—Doxorubicin—kidney cancer	4.91e-05	7.19e-05	CcSEcCtD
Pramipexole—Feeling abnormal—Doxorubicin—kidney cancer	4.73e-05	6.92e-05	CcSEcCtD
Pramipexole—Gastrointestinal pain—Doxorubicin—kidney cancer	4.7e-05	6.87e-05	CcSEcCtD
Pramipexole—Urticaria—Doxorubicin—kidney cancer	4.56e-05	6.68e-05	CcSEcCtD
Pramipexole—Body temperature increased—Doxorubicin—kidney cancer	4.54e-05	6.64e-05	CcSEcCtD
Pramipexole—Abdominal pain—Doxorubicin—kidney cancer	4.54e-05	6.64e-05	CcSEcCtD
Pramipexole—Hypersensitivity—Doxorubicin—kidney cancer	4.23e-05	6.19e-05	CcSEcCtD
Pramipexole—Asthenia—Doxorubicin—kidney cancer	4.12e-05	6.03e-05	CcSEcCtD
Pramipexole—Pruritus—Doxorubicin—kidney cancer	4.06e-05	5.94e-05	CcSEcCtD
Pramipexole—Diarrhoea—Doxorubicin—kidney cancer	3.93e-05	5.75e-05	CcSEcCtD
Pramipexole—Dizziness—Doxorubicin—kidney cancer	3.8e-05	5.56e-05	CcSEcCtD
Pramipexole—Vomiting—Doxorubicin—kidney cancer	3.65e-05	5.34e-05	CcSEcCtD
Pramipexole—Rash—Doxorubicin—kidney cancer	3.62e-05	5.3e-05	CcSEcCtD
Pramipexole—Dermatitis—Doxorubicin—kidney cancer	3.62e-05	5.29e-05	CcSEcCtD
Pramipexole—Headache—Doxorubicin—kidney cancer	3.6e-05	5.26e-05	CcSEcCtD
Pramipexole—Nausea—Doxorubicin—kidney cancer	3.41e-05	4.99e-05	CcSEcCtD
Pramipexole—DRD3—Signaling Pathways—RAF1—kidney cancer	7.76e-06	0.000145	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—CCND1—kidney cancer	7.76e-06	0.000145	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—JUN—kidney cancer	7.75e-06	0.000145	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—RELA—kidney cancer	7.73e-06	0.000144	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—POMC—kidney cancer	7.71e-06	0.000144	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—HIF1A—kidney cancer	7.69e-06	0.000144	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—CTNNB1—kidney cancer	7.69e-06	0.000143	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—KRAS—kidney cancer	7.68e-06	0.000143	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MTOR—kidney cancer	7.68e-06	0.000143	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—ERBB2—kidney cancer	7.68e-06	0.000143	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TSC2—kidney cancer	7.67e-06	0.000143	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—KRAS—kidney cancer	7.67e-06	0.000143	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—PTEN—kidney cancer	7.65e-06	0.000143	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CDKN1B—kidney cancer	7.64e-06	0.000143	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—CCND1—kidney cancer	7.64e-06	0.000143	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—JUN—kidney cancer	7.62e-06	0.000142	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—MAPK1—kidney cancer	7.6e-06	0.000142	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MTOR—kidney cancer	7.58e-06	0.000141	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PTGS2—kidney cancer	7.57e-06	0.000141	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—KIT—kidney cancer	7.57e-06	0.000141	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—APC—kidney cancer	7.57e-06	0.000141	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—CTNNB1—kidney cancer	7.56e-06	0.000141	CbGpPWpGaD
Pramipexole—HTR1A—GPCR downstream signaling—PIK3CA—kidney cancer	7.51e-06	0.00014	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—PTEN—kidney cancer	7.49e-06	0.00014	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IL2—kidney cancer	7.48e-06	0.00014	CbGpPWpGaD
Pramipexole—HTR2C—GPCR downstream signaling—PIK3CA—kidney cancer	7.47e-06	0.000139	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—APC—kidney cancer	7.45e-06	0.000139	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—KIT—kidney cancer	7.45e-06	0.000139	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—KRAS—kidney cancer	7.42e-06	0.000138	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—KRAS—kidney cancer	7.38e-06	0.000138	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—PTEN—kidney cancer	7.37e-06	0.000138	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—KDR—kidney cancer	7.35e-06	0.000137	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CCND1—kidney cancer	7.29e-06	0.000136	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—JUN—kidney cancer	7.28e-06	0.000136	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—PIK3CA—kidney cancer	7.26e-06	0.000136	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PTGS2—kidney cancer	7.26e-06	0.000135	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—MAPK3—kidney cancer	7.25e-06	0.000135	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CTNNB1—kidney cancer	7.22e-06	0.000135	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CDKN1B—kidney cancer	7.21e-06	0.000135	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—POMC—kidney cancer	7.2e-06	0.000134	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—KRAS—kidney cancer	7.18e-06	0.000134	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—MAPK3—kidney cancer	7.13e-06	0.000133	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—BRAF—kidney cancer	7.11e-06	0.000133	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CDKN1B—kidney cancer	7.11e-06	0.000133	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—POMC—kidney cancer	7.09e-06	0.000132	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—PIK3CA—kidney cancer	7.06e-06	0.000132	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL2—kidney cancer	7.05e-06	0.000132	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—PIK3CA—kidney cancer	7.05e-06	0.000132	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—PTEN—kidney cancer	7.04e-06	0.000131	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—RAF1—kidney cancer	7.01e-06	0.000131	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—BRAF—kidney cancer	7e-06	0.000131	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—RELA—kidney cancer	6.98e-06	0.00013	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL2—kidney cancer	6.96e-06	0.00013	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—ERBB2—kidney cancer	6.93e-06	0.000129	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—VEGFA—kidney cancer	6.91e-06	0.000129	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—MAPK1—kidney cancer	6.9e-06	0.000129	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CCND1—kidney cancer	6.88e-06	0.000128	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—JUN—kidney cancer	6.86e-06	0.000128	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MTOR—kidney cancer	6.84e-06	0.000128	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—TP53—kidney cancer	6.82e-06	0.000127	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—PIK3CA—kidney cancer	6.82e-06	0.000127	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CTNNB1—kidney cancer	6.81e-06	0.000127	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—PTEN—kidney cancer	6.79e-06	0.000127	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—MAPK1—kidney cancer	6.79e-06	0.000127	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CCND1—kidney cancer	6.78e-06	0.000127	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—PIK3CA—kidney cancer	6.78e-06	0.000127	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—KIT—kidney cancer	6.77e-06	0.000126	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—APC—kidney cancer	6.77e-06	0.000126	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—JUN—kidney cancer	6.77e-06	0.000126	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—VEGFA—kidney cancer	6.77e-06	0.000126	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—RAF1—kidney cancer	6.76e-06	0.000126	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—RELA—kidney cancer	6.73e-06	0.000126	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—RAF1—kidney cancer	6.73e-06	0.000126	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CTNNB1—kidney cancer	6.72e-06	0.000125	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—RELA—kidney cancer	6.7e-06	0.000125	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—ERBB2—kidney cancer	6.69e-06	0.000125	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—VEGFA—kidney cancer	6.66e-06	0.000124	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—ERBB2—kidney cancer	6.66e-06	0.000124	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—PTEN—kidney cancer	6.64e-06	0.000124	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MTOR—kidney cancer	6.6e-06	0.000123	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PTEN—kidney cancer	6.6e-06	0.000123	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—PIK3CA—kidney cancer	6.59e-06	0.000123	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—PIK3CA—kidney cancer	6.59e-06	0.000123	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MTOR—kidney cancer	6.57e-06	0.000123	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—PTEN—kidney cancer	6.55e-06	0.000122	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—RAF1—kidney cancer	6.55e-06	0.000122	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—MAPK3—kidney cancer	6.54e-06	0.000122	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—RELA—kidney cancer	6.52e-06	0.000122	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—KRAS—kidney cancer	6.51e-06	0.000122	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	6.49e-06	0.000121	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—PIK3CA—kidney cancer	6.48e-06	0.000121	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—ERBB2—kidney cancer	6.48e-06	0.000121	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—POMC—kidney cancer	6.45e-06	0.00012	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CDKN1B—kidney cancer	6.42e-06	0.00012	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—KRAS—kidney cancer	6.41e-06	0.00012	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—MAPK3—kidney cancer	6.4e-06	0.000119	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MTOR—kidney cancer	6.39e-06	0.000119	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—BRAF—kidney cancer	6.37e-06	0.000119	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—MYC—kidney cancer	6.36e-06	0.000119	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—VEGFA—kidney cancer	6.36e-06	0.000119	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PTEN—kidney cancer	6.33e-06	0.000118	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MAPK3—kidney cancer	6.3e-06	0.000118	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL2—kidney cancer	6.28e-06	0.000117	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—MYC—kidney cancer	6.23e-06	0.000116	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—MAPK1—kidney cancer	6.22e-06	0.000116	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CDKN1B—kidney cancer	6.2e-06	0.000116	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	6.17e-06	0.000115	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	6.17e-06	0.000115	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PTGS2—kidney cancer	6.15e-06	0.000115	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MYC—kidney cancer	6.13e-06	0.000114	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CCND1—kidney cancer	6.13e-06	0.000114	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—JUN—kidney cancer	6.11e-06	0.000114	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—MAPK1—kidney cancer	6.09e-06	0.000114	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CTNNB1—kidney cancer	6.07e-06	0.000113	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL2—kidney cancer	6.07e-06	0.000113	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL2—kidney cancer	6.03e-06	0.000113	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MAPK3—kidney cancer	6.01e-06	0.000112	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CDKN1B—kidney cancer	6e-06	0.000112	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—VEGFA—kidney cancer	5.99e-06	0.000112	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MAPK1—kidney cancer	5.99e-06	0.000112	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	5.98e-06	0.000112	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—RAF1—kidney cancer	5.94e-06	0.000111	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—VEGFA—kidney cancer	5.91e-06	0.00011	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—RELA—kidney cancer	5.91e-06	0.00011	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CCND1—kidney cancer	5.91e-06	0.00011	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PTEN—kidney cancer	5.91e-06	0.00011	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—JUN—kidney cancer	5.9e-06	0.00011	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	5.9e-06	0.00011	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	5.89e-06	0.00011	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCND1—kidney cancer	5.88e-06	0.00011	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—ERBB2—kidney cancer	5.88e-06	0.00011	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—KRAS—kidney cancer	5.88e-06	0.00011	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—JUN—kidney cancer	5.87e-06	0.00011	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL2—kidney cancer	5.87e-06	0.00011	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	5.86e-06	0.000109	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MYC—kidney cancer	5.85e-06	0.000109	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—RAF1—kidney cancer	5.84e-06	0.000109	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	5.83e-06	0.000109	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	5.83e-06	0.000109	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—RELA—kidney cancer	5.82e-06	0.000109	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MTOR—kidney cancer	5.8e-06	0.000108	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—ERBB2—kidney cancer	5.78e-06	0.000108	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—KRAS—kidney cancer	5.75e-06	0.000107	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCND1—kidney cancer	5.72e-06	0.000107	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MAPK1—kidney cancer	5.72e-06	0.000107	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—JUN—kidney cancer	5.71e-06	0.000107	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PTEN—kidney cancer	5.71e-06	0.000107	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MTOR—kidney cancer	5.71e-06	0.000106	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PTEN—kidney cancer	5.68e-06	0.000106	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MAPK3—kidney cancer	5.67e-06	0.000106	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CTNNB1—kidney cancer	5.67e-06	0.000106	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—KRAS—kidney cancer	5.66e-06	0.000106	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MAPK3—kidney cancer	5.6e-06	0.000104	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PTEN—kidney cancer	5.52e-06	0.000103	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MYC—kidney cancer	5.52e-06	0.000103	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MYC—kidney cancer	5.44e-06	0.000102	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CDKN1B—kidney cancer	5.44e-06	0.000102	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—KRAS—kidney cancer	5.4e-06	0.000101	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—PIK3CA—kidney cancer	5.4e-06	0.000101	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MAPK1—kidney cancer	5.4e-06	0.000101	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PTEN—kidney cancer	5.36e-06	0.0001	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	5.36e-06	0.0001	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	5.35e-06	9.99e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—VEGFA—kidney cancer	5.34e-06	9.97e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL2—kidney cancer	5.33e-06	9.94e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MAPK1—kidney cancer	5.32e-06	9.94e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—RAF1—kidney cancer	5.32e-06	9.92e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—RELA—kidney cancer	5.29e-06	9.88e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—PIK3CA—kidney cancer	5.29e-06	9.86e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	5.26e-06	9.82e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL2—kidney cancer	5.24e-06	9.78e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TP53—kidney cancer	5.22e-06	9.75e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—PIK3CA—kidney cancer	5.2e-06	9.71e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCND1—kidney cancer	5.19e-06	9.69e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MTOR—kidney cancer	5.19e-06	9.69e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—JUN—kidney cancer	5.18e-06	9.67e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—VEGFA—kidney cancer	5.15e-06	9.62e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CTNNB1—kidney cancer	5.14e-06	9.6e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—VEGFA—kidney cancer	5.13e-06	9.57e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TP53—kidney cancer	5.11e-06	9.54e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCND1—kidney cancer	5.11e-06	9.53e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—JUN—kidney cancer	5.1e-06	9.51e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—KRAS—kidney cancer	5.1e-06	9.51e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	5.06e-06	9.44e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MAPK3—kidney cancer	5.05e-06	9.43e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TP53—kidney cancer	5.03e-06	9.39e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—KRAS—kidney cancer	5.03e-06	9.38e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PTEN—kidney cancer	5.01e-06	9.35e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—VEGFA—kidney cancer	4.99e-06	9.31e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—PIK3CA—kidney cancer	4.96e-06	9.27e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PTEN—kidney cancer	4.93e-06	9.2e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MYC—kidney cancer	4.91e-06	9.17e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MAPK3—kidney cancer	4.88e-06	9.1e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	4.87e-06	9.09e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MAPK3—kidney cancer	4.85e-06	9.05e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MAPK1—kidney cancer	4.81e-06	8.97e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TP53—kidney cancer	4.8e-06	8.96e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—PIK3CA—kidney cancer	4.79e-06	8.94e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL2—kidney cancer	4.77e-06	8.9e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MYC—kidney cancer	4.74e-06	8.85e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MAPK3—kidney cancer	4.72e-06	8.81e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MYC—kidney cancer	4.72e-06	8.81e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—PIK3CA—kidney cancer	4.68e-06	8.74e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PIK3CA—kidney cancer	4.66e-06	8.7e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCND1—kidney cancer	4.65e-06	8.67e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MAPK1—kidney cancer	4.64e-06	8.66e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—JUN—kidney cancer	4.64e-06	8.66e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—PIK3CA—kidney cancer	4.62e-06	8.62e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MAPK1—kidney cancer	4.62e-06	8.62e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	4.6e-06	8.59e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MYC—kidney cancer	4.59e-06	8.57e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—KRAS—kidney cancer	4.54e-06	8.47e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TP53—kidney cancer	4.53e-06	8.45e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—VEGFA—kidney cancer	4.53e-06	8.45e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MAPK1—kidney cancer	4.49e-06	8.38e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PTEN—kidney cancer	4.49e-06	8.37e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TP53—kidney cancer	4.47e-06	8.34e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PIK3CA—kidney cancer	4.46e-06	8.33e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—VEGFA—kidney cancer	4.45e-06	8.31e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—KRAS—kidney cancer	4.38e-06	8.18e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—KRAS—kidney cancer	4.36e-06	8.14e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MAPK3—kidney cancer	4.28e-06	7.99e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—KRAS—kidney cancer	4.24e-06	7.91e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MAPK3—kidney cancer	4.21e-06	7.86e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PIK3CA—kidney cancer	4.17e-06	7.78e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MYC—kidney cancer	4.16e-06	7.77e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MYC—kidney cancer	4.1e-06	7.65e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MAPK1—kidney cancer	4.07e-06	7.6e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	4.05e-06	7.56e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TP53—kidney cancer	4.03e-06	7.53e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	4.03e-06	7.51e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MAPK1—kidney cancer	4.01e-06	7.48e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	4.01e-06	7.48e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PIK3CA—kidney cancer	3.9e-06	7.27e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TP53—kidney cancer	3.89e-06	7.27e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TP53—kidney cancer	3.87e-06	7.23e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—KRAS—kidney cancer	3.85e-06	7.18e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	3.83e-06	7.15e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—KRAS—kidney cancer	3.79e-06	7.07e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PIK3CA—kidney cancer	3.78e-06	7.06e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TP53—kidney cancer	3.77e-06	7.03e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MYC—kidney cancer	3.73e-06	6.96e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	3.65e-06	6.81e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CA—kidney cancer	3.53e-06	6.6e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	3.48e-06	6.49e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—KRAS—kidney cancer	3.44e-06	6.43e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TP53—kidney cancer	3.42e-06	6.38e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TP53—kidney cancer	3.36e-06	6.28e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	3.16e-06	5.91e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TP53—kidney cancer	3.06e-06	5.71e-05	CbGpPWpGaD
